OmniAb logo

OmniAbNASDAQ: OABI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 September 2021

Next earnings report:

20 March 2025

Last dividends:

N/A

Next dividends:

N/A
$480.42 M
-38%vs. 3y high
65%vs. sector
-vs. 3y high
-vs. sector
-81%vs. 3y high
54%vs. sector
-24%vs. 3y high
87%vs. sector

Price

after hours | Fri, 15 Nov 2024 21:27:38 GMT
$3.97-$0.25(-5.92%)

Dividend

No data over the past 3 years
$4.17 M$11.27 M
$4.17 M-$16.37 M

Analysts recommendations

Institutional Ownership

OABI Latest News

OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates
zacks.com12 November 2024 Sentiment: NEGATIVE

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.16 per share a year ago.

OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript
seekingalpha.com10 August 2024 Sentiment: POSITIVE

OmniAb, Inc. (NASDAQ:OABI ) Q2 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President and Chief Executive Officer Conference Call Participants Michael Sonntag - Leerink Partners Chad Wiatrowski - TD Cowen Stephen Willey - Stifel Conor McNamara - RBC Capital Markets Operator Good afternoon and welcome to OmniAb Incorporated 2024 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

OmniAb to Participate in the Jefferies Global Healthcare Conference
businesswire.com20 May 2024 Sentiment: NEUTRAL

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be presenting a corporate overview on Wednesday, June 5th at 8:00 a.m. Eastern time and will be holding one-on-one meetings with investors. A live and archived webcast of the presentation will be available in the Investors section of OmniAb's websit.

OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript
Seeking Alpha20 March 2024 Sentiment: NEUTRAL

OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript

OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
Zacks Investment Research28 February 2024 Sentiment: POSITIVE

OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

OmniAb: Hold For Growth
Seeking Alpha25 September 2023 Sentiment: POSITIVE

OmniAb is a long-term growth story. The company's Q2 earnings call reported nice growth in its projects and partners. As a newly formed company with lumpy revenues and limited liquidity, OmniAb still has work to do to support a bull thesis.

OmniAb, Inc. (OABI) Q2 2023 Earnings Call Transcript
Seeking Alpha12 August 2023 Sentiment: POSITIVE

OmniAb, Inc. (NASDAQ:OABI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Kurt Gustafson - CFO Matthew Foehr - President, CEO Conference Call Participants Puneet Souda - Leerink Partners Robyn Karnauskas - Truist Securities Stephen Willey - Stifel Jack Siedow - Craig-Hallum Chad Wiatrowski - TD Cowen Brandon Carney - B.Riley Operator Good afternoon, and welcome to OmniAb, Inc. Second Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

7 Biotech Stocks With Huge Return Potential for Long-Term Investors
InvestorPlace26 April 2023 Sentiment: POSITIVE

Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can't just introduce health-related products directly to the market.

OmniAb, Inc. (OABI) Q4 2022 Earnings Call Transcript
Seeking Alpha02 April 2023 Sentiment: NEUTRAL

OmniAb, Inc. (NASDAQ:OABI ) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Kurt Gustafson - CFO Matt Foehr - President and CEO Conference Call Participants Nishant Gandhi - Truist Securities Joseph Pantginis - H.C. Wainwright & Co. Steven Mah - TD Cowen Puneet Souda - SVB Securities Yuan Zhi - B.

What type of business is OmniAb?

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

What sector is OmniAb in?

OmniAb is in the Healthcare sector

What industry is OmniAb in?

OmniAb is in the Biotechnology industry

What country is OmniAb from?

OmniAb is headquartered in United States

When did OmniAb go public?

OmniAb initial public offering (IPO) was on 30 September 2021

What is OmniAb website?

https://www.omniab.com

Is OmniAb in the S&P 500?

No, OmniAb is not included in the S&P 500 index

Is OmniAb in the NASDAQ 100?

No, OmniAb is not included in the NASDAQ 100 index

Is OmniAb in the Dow Jones?

No, OmniAb is not included in the Dow Jones index

When was OmniAb the previous earnings report?

No data

When does OmniAb earnings report?

The next expected earnings date for OmniAb is 20 March 2025